MAPK3 and Hypoglycemia: In our experiments, we found that dapagliflozin can reduce the phosphorylation of ERK1/2 in HRMECs caused by high glucose, and provides new theoretical support to understand the anti-apoptotic mechanism of DAPA independent of hypoglycemia.